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The aim of this study was to compare the laeverin level in maternal serum from first trimester 
(11-14 weeks) of pregnancy between normal pregnancies and pregnancies that later developed 
preeclampsia (PE).  
 
Material and methods 
This was a case-cohort study. The laeverin concentration was measured in cases with preterm 
PE (n=55), term PE (n=95) and a reference group of randomly selected women with normal 
pregnancy outcome (n=200) in stored serum samples collected from the double-test as part of 
the combined first trimester trisomy 21 screening program. The samples were thawed and 
analyzed for laeverin. The median gestational age at blood sampling was 77 days (range 57-
96 days). Multiple regression analysis was performed to establish a normal median. 
Concentrations were converted to multiples of the median (MoM) and groups were compared 
using the Mann-Whitney U-test.   
 
Results 
In the reference group laeverin was significantly correlated with gestational age (r=0.18, 
p=0.01) and its concentration ranged from 41 – 393 µg/L. No significant differences in the 
median laeverin MoM were found between the reference group (1.01 MoM) and cases with 
preterm PE (0.98 MoM) or term PE (0.96 MoM).  
 
Conclusion 





Preeclampsia (PE) affects around 3-5% of pregnancies and is a major cause of maternal and 
perinatal mortality and morbidity [1]. The pathogenesis of PE is not fully understood, but 
placental and endothelial dysfunction seem to play important roles [2]. Several biomarkers 
have been suggested to predict PE, but no individual marker with sufficient specificity and 
sensitivity has been identified. Search for an appropriate biomarker that could accurately 
predict the development of this placenta-specific disorder is ongoing.  
 
Laeverin, also known as aminopeptidase Q, is a placenta specific membrane-bound 
aminopeptidase. The protein was first reported by Fujiwara et al. in 2004 and was found to be 
expressed by the human trophoblast cells [3]. Laeverin is suggested to play a role in 
placentation by a regulating molecular mechanism associated with extravillous trophoblast 
invasion. Laeverin expression is detectable from very early stage of placentation at around 
four weeks of gestation [4].  
 
It has been suggested that laeverin may have a role in the pathogenesis of PE [5]. This is 
supported by the finding of laeverin gene being significantly upregulated (10 fold) in 
placentas from pregnancies complicated by severe PE [6]. Furthermore, in the second 
trimester, maternal plasma laeverin level was found to be reduced in pregnancies that later 
developed PE [7].   
 
We hypothesized that laeverin might be altered in the first trimester maternal serum in 
pregnancies who later develop PE. The aim of this study was to compare the first trimester 
maternal serum laeverin concentrations between normal pregnancies and pregnancies that 
 
 
were complicated by PE. Furthermore, we wanted to explore potential associations to figure 
out whether first trimester laeverin could be used as a screening test for PE.  
 
 
Material & Methods 
 
Study population 
This study was conducted on a cohort of nulliparous women with singleton pregnancies 
consecutively enrolled into the first trimester combined screening program for trisomy 21 in 
the period 1 January 2005 to 31 December 2010 at Copenhagen University Hospital Hvidovre, 
Denmark. Data were obtained from the local fetal medicine database (Astraia software, 
München, Germany) and the local obstetric database. The SPSS sample function (Mersenne 
Twister random number generator) was used for random selection of 200 reference cases from 
the cohort restricted to those with delivery at ≥ 37 weeks + 0 days, a birth weight appropriate 
for gestational age (±2SD) [8] and no registered diagnosis of PE. In pregnancies with a 
registered diagnosis of PE, the diagnosis was validated by scrutinization of the medical 
records to ensure that the diagnostic criteria were fulfilled. In total, 100 of 237 cases with 
term PE were selected randomly with the SPSS sample function. All cases with preterm PE 
were included (n=61).    
 
The study was approved by the Danish Research Ethics Committee (H-1-2012-097) and the 
Data Protection Agency in Denmark (01820 HVH-2012-035). 
 
Serum sample analysis 
The blood samples were collected as part of the first trimester combined screening program 
for trisomy 21 between 8 and 14 weeks of gestation. Serum samples were retrieved from 
storage, thawed and analyzed for laeverin. It was not possible to localize 11 samples from 
storage-freezer in cases with PE. The concentration of laeverin (aminopeptidase Q) was 
measured using a commercial enzyme-linked immunosorbent assay (ELISA) (EIAab Science 
 
 
Co Ltd., Wuhan, China). The measurement was performed in duplicate according to the 
manufacturer’s specifications. A parallelism was observed between the laeverin standard 
curve and two serum samples diluted with sample diluent 1:25, 1:50, 1:100 and 1:200 (Figure 
1).  A serum sample dilution of 1: 50 was chosen to cover the concentration range 20-500 
µg/L laeverin. The inter-assay variation was 14.0 % at 133 µg/L and 21.6 % at 14 µg/L (n=11). 
The lower detection limit was 0.05 µg/L.  
 
Outcome measures 
PE was defined as gestational hypertension with proteinuria according to the International 
Society for the Study of Hypertension in Pregnancy (ISSHP) [9]. Gestational hypertension 
was defined as either a systolic blood pressure exceeding 140 mmHg or a diastolic 
bloodpressure exceeding 90 mmHg (based on two measurements taken at least four hours 
apart) in a previously normotensive woman after 20 weeks of gestation. The criteria for 
proteinuria were ≥300 mg/24 hours or ‘2+’ on urine dipstick testing. PE cases were stratified 
into preterm PE (delivery < 37 weeks + 0 days) and term PE (delivery ≥ 37 weeks + 0 days). 
Small-for-gestational age (SGA) was defined as a birthweight deviation ≥ 2 standard 
deviations from the mean birthweight in normal pregnancies according to gestational age [8]. 
 
Statistical analyses 
Data distribution was checked for normality using the Shapiro-Wilk test, and log-transformed 
to achieve normal distribution if required. Multiple regression analysis was performed to 
establish a normal median for laeverin in the reference group. Laeverin concentrations were 
then transformed to multiples of the median (MoM) values in both cases and references. 
Groups were compared using the Mann-Whitney U-test or the Chi-Square test as appropriate. 
A p-value < 0.05 was considered significant. The statistical software packages SPSS 22.0 
 
 





The maternal characteristics for each outcome group are outlined and compared in Table 1. 
The body mass index (BMI) was significantly elevated in pregnancies with PE. In the 
reference group a positive correlation between the laeverin concentration (log transformed) 
and the gestational age was found (r=0.18, p=0.01). The laeverin concentration ranged from 
41 µg/L to 393 µg/L in the reference group. Figure 2 shows the laeverin concentration 
according to gestational age in the different outcome groups. In a multivariate regression 
analysis of the reference group, the gestational age and maternal weight contributed 
significantly to the model describing the normal median for laeverin as µg/L = 10exp 
(0.005*gestational age*days-1 + 0.003*maternal weight*kg-1 + 1.925). The laeverin MoM 
medians in the outcome groups are outlined in Table 2. No significant difference was found 
between the reference group and cases with PE. A further stratification of cases with PE into 
preterm and term PE, and the fetus being small-for-gestational age or not, showed no 





To the best of our knowledge this is the first study reporting first trimester maternal serum 
laeverin concentrations in pregnancies that were complicated by PE later compared to normal 
pregnancies. We found no significant difference in the laeverin MoM values between the PE 
and the reference groups. We had expected an altered level of laeverin in cases with preterm 
PE, because of the known strong association with impaired placentation in this group and the 
reported significance of laeverin in the early process of placentation [4,10]. However, the 
laeverin levels were also similar between the preterm and the term PE groups. 
 
We found a positive correlation between maternal serum laeverin concentration and 
gestational age in the late first trimester, which is in contrast to the finding of negative 
correlation reported in the second and third trimester [7]. However, the median laeverin 
concentrations measured during 8-14 weeks were higher compared to the values reported 
during 22-40 weeks. Although the differences in the study design (longitudinal vs. cross-
sectional) and the samples used for measuring laeverin (plasma vs. serum) may explain some 
variability, this is an interesting finding. Higher and increasing concentration in the first 
trimester may suggest that laeverin has an important role to play in the first trimester 
placentation process. Expression studies using first trimester placental samples and maternal 
blood obtained simultaneously, such as during termination of pregnancy, could provide more 
insight into the relationship between placental and maternal compartments. 
 
Maternal serum laeverin might be a biomarker of PE in the second and third trimester. In a 
recent study, Nystad et al.[7] report that second trimester maternal plasma laeverin was 
 
 
significantly reduced in pregnancies that developed PE. It was speculated that the reduction in 
laeverin during the development of PE was caused by trapping of laeverin in the placenta or 
in microvesicles in the fetal capillaries [5]. However, the study was based on only a few cases 
with PE (n=15) and therefore needs to be confirmed in larger series. 
     
The strength of our study is the inclusion of large number of cases with PE with validated 
diagnosis. It has previously been reported that Danish registry data might be restricted due to 
variability in the diagnostic criteria and reporting procedures for PE, which emphasizes the 
need for clinical validation [11,12]. We acknowledge that our sample size may not be large 
enough to detect a small difference in the laeverin concentration between cases and the 
reference group. However, such a small difference is unlikely to be relevant in the context of 
screening for PE. 
 
In conclusion, first trimester maternal serum laeverin is not altered in pregnancies that are 
complicated by PE later in gestation compared to normal pregnancies. Maternal serum 
laeverin measured in the first trimester does not appear to predict PE and is therefore not a 
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Table 1.  
Maternal characteristics with values in median (range) and n (%) 
 
 Reference group 
 (n=200) 
Term PE (n=95) Preterm PE 
(n=55) 
Age (years) 29.0 (16-40) 28.0 (19-39)* 29.0 (18-44) 




Caucasian ethnicity 179 (89.5) 85 (89.5) 50 (90.9) 
Cigarette smoker 14 (7.0) 6 (6.3) 5 (9.1) 
Gestaional age at blood sampling 
(days) 
77 (57-96) 77 (57-94) 77 (57-96) 







Laeverin MoM values in different outcome groups 
 
Outcome group Median IQR p-valuea 
Reference group (n=200) 1.01 0.56 - 
PE (n=150) 0.98 0.67 0.535 
 - Term PE (n=95) 0.96 0.61 0.725 
 - Preterm PE (n=55) 0.98 0.79 0.483 
 - PE + SGA (n=27)b 1.02 0.79 0.702 
aMann-Whitney U-test (reference group vs outcome group) 







Figure 1.  




Figure 2.  
Maternal serum laeverin concentration according to gestational age in different outcome 
groups. 
 
 
 


